Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibition as a prototype for synthetic lethal screens.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2013

Liu Xuesong

Abstract excerpt

Although DNA damaging chemotherapy and radiation therapy remain the main stay of current treatments for cancer patient, these therapies usually have toxic side effect and narrow therapeutic window. One of the challenges in cancer drug discovery is how to identify drugs that selectively kill cancer cells while leaving the normal cell intact. Recently, synthetic lethality has been applied to cancer drug discovery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Enzyme Inhibitors

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to RNA Interference

Share to RNA, Small Interfering

Source

Identifiers

PMID: 23436410
DOI: 10.1007/978-1-62703-311-4_9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibition as a prototype for synthetic lethal screens.PMID 23436410Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

Application and research progress of synthetic lethality in the development of anticancer therapeutic drugsSemantic proximity Read ↗

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.Semantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Evolving DNA repair synthetic lethality targets in cancerSemantic proximity Read ↗

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Semantic proximity Read ↗

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read ↗

Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeuticsSemantic proximity Read ↗

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directionsSemantic proximity Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.